drugset / Trial / NCT03062618

A Study of PRCL-02 in Healthy Volunteers and Plaque Psoriasis

NCT03062618 ↗

Phase 1 Completed 50 enrolled PRCL Research Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

This study consists of three parts: single oral dose escalation in healthy volunteers (Part A), and multiple oral dose escalations in healthy volunteers (Part B) and in participants with chronic plaque psoriasis (Part C)

Timeline

Start
2017-02-20
Primary completion
2018-02-08
Completion
2018-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject PRCL-02 Unknown 4 mg Oral

Indications